Drug Approval | December 30, 2024
Cenexi's Fontenay manufacturing facility receives 10 observations in ANSM inspection
Cenexi is committed to working closely with the ANSM to address the observations
Cenexi is committed to working closely with the ANSM to address the observations
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
The facility was inspected from May 7 to May 17, 2024
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Subscribe To Our Newsletter & Stay Updated
